Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with Covid-19.

ABSTRACT:

Background

Nirmatrelvir is an orally administered severe acute respiratory syndrome coronavirus 2 main protease (M^pro) inhibitor with potent pan-human-coronavirus activity in vitro.

Methods

We conducted a phase 2-3 double-blind, randomized, controlled trial in which symptomatic, unvaccinated, nonhospitalized adults at high risk for progression to severe coronavirus disease 2019 (Covid-19) were assigned in a 1:1 ratio to receive either 300 mg of nirmatrelvir plus 100 mg of ritonavir (a pharmacokinetic enhancer) or placebo every 12 hours for 5 days. Covid-19-related hospitalization or death from any cause through day 28, viral load, and safety were evaluated.

Results

A total of 2246 patients underwent randomization; 1120 patients received nirmatrelvir plus ri

SUBMITTER: Hammond J 

PROVIDER: S-EPMC8908851 | biostudies-literature | 2022 Apr

REPOSITORIES: biostudies-literature